Oppenheimer & Co’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Oppenheimer & Co’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-501	Closed	-$100K	–	1595
2021 Q3	$100K	Hold	501	–	–	﹤0.01%	1451
2021 Q2	$128K	Sell	501 -12	-2%	-$3K	﹤0.01%	1459
2021 Q1	$136K	Buy	+513	New	+$162K	﹤0.01%	1389

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Oppenheimer & Co's EIGR Position: Q4 2021 in Review

Oppenheimer & Co sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2021, closing a stake of 501 shares — an estimated $100K sold.

Oppenheimer & Co first reported a position in EIGR in Q1 2021 and held it in 3 quarters. The position peaked at $136K in Q1 2021. 85 funds tracked by Wall St. Rank hold EIGR as of Q4 2021.

Oppenheimer & Co reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Oppenheimer & Co sold 501 Eiger BioPharmaceuticals, Inc. shares in Q4 2021, an estimated $100K.
Oppenheimer & Co first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2021 and held it in 3 quarters.
Oppenheimer & Co's Eiger BioPharmaceuticals, Inc. position peaked at $136K in Q1 2021.
85 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2021.

Based on Oppenheimer & Co's 13F filing for Q4 2021, filed 2 Feb 2022.